OBJECTIVES: To compare clinical and MRI parameters between patients with clinically isolated syndrome and those converting to clinically definite multiple sclerosis within 2 years, to identify volumetric MRI predictors of this conversion and to assess effect of early relapses. METHODS: The SET study comprised 220 patients with clinically isolated syndrome treated with interferon beta (mean age, 29 years; Expanded Disability Status Scale, 1.5). Three patients with missing data were excluded from the analysis. Physical disability, time to clinically definite multiple sclerosis and volumetric MRI data were recorded for 2 years. RESULTS: Patients reaching clinically definite multiple sclerosis showed impaired recovery of neurological function, faster decrease in corpus callosum cross-sectional area, higher T2 lesion volume and more contrast-enhancing lesions. Six-month decrease in corpus callosum cross-sectional area (≥ 1%) and baseline T2 lesion volume (≥ 5 cm(3)) predicted clinically definite multiple sclerosis within 2 years (hazard ratios 2.5 and 1.8, respectively). Of 22 patients fulfilling both predictive criteria, 83% reached clinically definite multiple sclerosis (hazard ratio 6.5). More relapses were associated with poorer recovery of neurological function and accelerated brain atrophy. CONCLUSIONS: Neurological impairment is more permanent, brain atrophy is accelerated and focal inflammatory activity is greater in patients converting to clinically definite multiple sclerosis. Six-month corpus callosum atrophy and baseline T2 lesion volume jointly help predict individual risk of clinically definite multiple sclerosis. Early relapses contribute to permanent damage of the central nervous system.

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Zobrazit více v PubMed

Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, et al. (2011) MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 82: 176–179. PubMed

Tintore M, Rovira A, Rio J, Nos C, Grive E, et al. (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67: 968–972. PubMed

Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, et al. (2003) Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 126: 2323–2332. PubMed

Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, et al. (2010) Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 81: 204–208. PubMed

Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, et al. (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364: 1489–1496. PubMed

Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, et al. (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126: 433–437. PubMed

Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, et al. (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116 (Pt 1): 135–146. PubMed

O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, et al. (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121 (Pt 3): 495–503. PubMed

Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, et al. (2012) Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg 114: 940–946. PubMed

Vaneckova M, Kalincik T, Krasensky J, Horakova D, Havrdova E, et al. (2012) Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. Eur Neurol 68: 23–27. PubMed

Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, et al.. (2012) Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand. PubMed

Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, et al. (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346: 158–164. PubMed

Tintore M, Rovira A, Arrambide G, Mitjana R, Rio J, et al. (2010) Brainstem lesions in clinically isolated syndromes. Neurology 75: 1933–1938. PubMed

Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, et al. (2002) Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73: 141–147. PubMed PMC

Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, et al. (2004) Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127: 1101–1107. PubMed

Tintore M, Rovira A, Rio J, Tur C, Pelayo R, et al. (2008) Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 70: 1079–1083. PubMed

Sigal T, Shmuel M, Mark D, Gil H, Anat A (2012) Diffusion tensor imaging of corpus callosum integrity in multiple sclerosis: correlation with disease variables. J Neuroimaging 22: 33–37. PubMed

Mesaros S, Rocca MA, Riccitelli G, Pagani E, Rovaris M, et al. (2009) Corpus callosum damage and cognitive dysfunction in benign MS. Human Brain Mapping 30: 2656–2666. PubMed PMC

Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, et al. (2009) Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72: 800–805. PubMed

Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 (Pt 11): 2059–2069. PubMed

Sailer M, O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, et al. (1999) Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52: 599–606. PubMed

Miller DH, Ormerod IE, McDonald WI, MacManus DG, Kendall BE, et al. (1988) The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry 51: 1569–1571. PubMed PMC

Hawkins CP, Mackenzie F, Tofts P, du Boulay EP, McDonald WI (1991) Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 114 (Pt 2): 801–810. PubMed

Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5: 158–170. PubMed

Calabrese M, Rinaldi F, Mattisi I, Bernardi V, Favaretto A, et al. (2011) The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 77: 257–263. PubMed

Bergsland N, Horakova D, Dwyer MG, Dolezal O, Seidl ZK, et al.. (2012) Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. AJNR Am J Neuroradiol. PubMed PMC

Hutchinson M (2011) Relapses do not matter in relation to long-term disability: commentary. Mult Scler 17: 1417. PubMed

Lublin FD, Baier M, Cutter G (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61: 1528–1532. PubMed

Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73: 1616–1623. PubMed PMC

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, et al. (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133: 1914–1929. PubMed PMC

Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343: 1430–1438. PubMed

Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, et al. (2012) Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PLoS One 6: e22444. PubMed PMC

Quantitative brain morphometry identifies cerebellar, cortical, and subcortical gray and white matter atrophy in late-onset Tay-Sachs disease

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis

Monitoring of radiologic disease activity by serum neurofilaments in MS

Cognitive clinico-radiological paradox in early stages of multiple sclerosis

Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients

Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome

MRI correlates of disability progression in patients with CIS over 48 months

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome